Berkeley Lights announces technology collaboration to accelerate and improve gene therapy viral vector development and manufacturing
EMERYVILLE, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI) today announced a strategic collaboration with Thermo Fisher Scientific aimed at addressing challenges in commercial-scale viral vector manufacturing. The partnership, which began in December of 2020, brings together Berkeley Lights’ leadership in functional biology characterization with Thermo Fisher’s expertise in viral vector manufacturing and analytics. Together, the companies are collaborating on a next-generation workflow using the Berkeley Lights Platform to accelerate and improve the development of stable AAV (Adeno-Associated Viral) and LV (Lentiviral) vector producer cell lines.
The industry’s reliance on transient expression for production limits novel cell and gene therapies from reaching more patients because transient transfection suffers from limited output, challenging batch-to-batch reproducibility, high cost, and complex supply chain issues. The workflows under development are designed to deliver stable AAV and LV producer lines on clinically relevant timelines which overcome the limitations of transient expression by providing the yield, consistency, and quality required for large-scale and commercial cGMP viral vector manufacturing to accelerate entry of cell and gene therapy products into the clinic and marketplace, not only for rare diseases but also for more common indications.
“We are very pleased with the scientific progress using Berkeley Lights’ platform, which moves us towards highly scalable, cost-effective processes that leverage Thermo Fisher’s end-to-end solutions for viral vector development and manufacturing,” said Richard Snyder, Vice President, Science and Technology, Pharma Services at Thermo Fisher Scintific.
“By developing a solution that rapidly screens thousands of candidate producer clones, we have the potential to transform how viral vectors are developed and manufactured at industrial scale,” said Troy Lionberger, PhD, VP Technology and Business Development at Berkeley Lights.
This effort builds on the foundation of Thermo Fisher’s viral vector manufacturing and development experience, and the Berkeley Lights OptoTM Assure Cell Line Development workflow that is focused on identifying clones with high product yield and favorable manufacturability profiles early in cell line development.
About Berkeley Lights
Forward Looking Statement
Berkeley Lights’ Beacon® and Lightning™ systems and Culture Station™ instrument are FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.